Recce Pharmaceuticals reported positive results from its recent study on RECCE 327 against the multidrug-resistant pathogen Acinetobacter baumannii.

R327 demonstrated rapid and sustained bactericidal activity in primary human epidermal keratinocytes, achieving a greater than 6.5 log reduction within the first hour, below the limit of quantification, and maintaining this efficacy over 24 hours.

"These outstanding results highlight the potent efficacy of R327 in combating MDR bacteria, a significant global health challenge," said Recce Pharmaceuticals CEO James Graham.

The results support ongoing and future Phase 2 trials, especially for urinary tract infections and urosepsis.